All In Biotech

Drug Trial Radar · NCT07055087

Prevent Cognitive Decline in GBA-associated Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled, 104-week Proof-of-concept Study to Evaluate the Efficacy of Intravenous Prasinezumab in Participants With Parkinson's Disease Carrying a Severe Mutation in the GBA Gene

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2030

Study completion May 2031

Sponsor

Lead sponsor
University Hospital TuebingenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene. The duration of the intervention per patient will be 104 weeks with monthly infusions. The investigators plan to enroll 120 participants (60 participants per treatment arm). This study will be conducted across Europe in the following countries: France, Germany, Italy, Luxembourg, Spain, Sweden, UK.

Conditions

  • Parkinson's Disease

Interventions

  • PrasinezumabDrug

    Prasinezumab 1500 mg monthly infusion

  • Sodium ChlorideDrug

    Saline infusion (0,9 % sodium chloride) monthly infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parkinson's Disease Cognitive Composite Score (PDCCS)Time frame: week 104

Locations

11 sites in 7 countries. Site status is shown where the registry gives one.

  • Sorbonne University, Pitié-Salpêtrière Hospital

    Paris, France · Not yet recruiting

  • University Hospital C. G. Carus TU Dresden

    Dresden, Germany · Not yet recruiting

  • University Hospital Tubingen

    Tübingen, Germany · Recruiting

  • University of Brescia and ASST Spedali Civili of Brescia

    Brescia, Italy · Not yet recruiting

  • Fondazione IRCCS Ca' Granda Policlinico Hospital

    Milan, Italy · Not yet recruiting

  • University of Pavia

    Pavia, Italy · Not yet recruiting

  • University of Luxemburg

    Luxembourg, Luxembourg · Not yet recruiting

  • Hospital Universitario HM Puerta del Sur, Madrid

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario Virgen del Rocío, Sevilla

    Seville, Spain · Not yet recruiting

  • Karolinska University of Stockholm

    Stockholm, Sweden · Not yet recruiting

  • University of Oxford

    Oxford, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.